3D Fibroscreen SRL
3D Fibroscreen reported total assets of 501,766 € at the end of the 2025 financial year (annual accounts filed with the NBB on 02 Sep 2026).
The score of 3D Fibroscreen shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
3D Fibroscreen's annual accounts
| 2025 | |
|---|---|
| Net result | 25,057 € |
| Equity | 45,057 € |
| Cash | 464,675 € |
| EBITDA | 33,378 € |
| Total assets | 501,766 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Sep 2026
3D Fibroscreen's financial analysis
- Solvency9.0%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of 3D Fibroscreen
3D Fibroscreen's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1022.772.354
- VAT number
- BE1022772354
- Peppol
- Registered · 0208:1022772354 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Apr 2025
- Registered office
- 6041 Charleroi
- Latest accounts
- 2025 · filed on 02 Sep 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
3D Fibroscreen (SRL) has been based in Charleroi since 2025, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 25,057 € and equity of 45,057 €; its revenue is not published. Its solvency stands at 9.0%, below the median of its sector (58.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to 3D Fibroscreen
Companies in the same business, of comparable size and area, outside its group.
- Hemastatx Research and experimental development on natural sciences and engineering Charleroi · balance sheet 200,755 €
- Groovy.Bio Manufacture of pharmaceutical preparations Evergem · balance sheet 744,069 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- Ergotrics Research and experimental development on natural sciences and engineering Turnhout · balance sheet 376,384 €
- Blue3Berg Research and experimental development on natural sciences and engineering Zoersel · balance sheet 803,714 €
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- ILiAD Biotechnologies Research and experimental development on natural sciences and engineering Ghent · balance sheet €1.06m
- Elkedonia Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet 228,425 €
Frequently asked questions about 3D Fibroscreen
What is the revenue of 3D Fibroscreen?
3D Fibroscreen files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of 3D Fibroscreen?
In Belgium, the VAT number is the company number prefixed with BE: BE1022772354 for 3D Fibroscreen, if the company is VAT-registered. Its company number (CBE) is 1022.772.354.
Where is the registered office of 3D Fibroscreen?
According to the CBE register, the registered office of 3D Fibroscreen is in 6041 Charleroi.
What is the equity of 3D Fibroscreen?
At the close of the 2025 financial year, the equity of 3D Fibroscreen amounts to 45,057 €, a solvency of 9.0% of total assets.
Who manages 3D Fibroscreen?
The register lists 6 active mandates at 3D Fibroscreen. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of 3D Fibroscreen
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →